Cargando…

366. Association Between Gut Microbiota and Health-Related Quality of Life in Patients with Recurrent Clostridioides difficile Infection: Results from the PUNCH CD3 Clinical Trial

BACKGROUND: Recurrence of Clostridioides difficile infection (rCDI) substantially diminishes patients’ health-related quality of life (HRQL). The gut microbiome is known to play an important role in rCDI, but little is known about its relationship with HRQL. In this study, we assessed the relationsh...

Descripción completa

Detalles Bibliográficos
Autores principales:	Feuerstadt, Paul, Blount, Ken, Guo, Amy, Yang, Min, García-Horton, Viviana, Fillbrunn, Mirko, Tillotson, Glenn S, Gao, Yipeng, Dubberke, Erik R, Garey, Kevin W
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2023
Materias:	Abstract
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10676825/ http://dx.doi.org/10.1093/ofid/ofad500.436

Ejemplares similares

Effect of Fecal Microbiota, Live-Jslm (REBYOTA [RBL]) on Health-Related Quality of Life in Patients With Recurrent Clostridioides difficile Infection: Results From the PUNCH CD3 Clinical Trial
por: Garey, Kevin W, et al.
Publicado: (2023)

522. Significant Improvement in Health-Related Quality of Life (HRQL) with RBX2660: Results from a Phase 3 Randomized, Placebo-Controlled Trial in Recurrent Clostridioides Difficile Infection (PUNCH CD3)
por: Feuerstadt, Paul, et al.
Publicado: (2022)

Effect of fecal microbial transplantation on Clostridioides difficile infection: dysbiosis, metabolites and health related quality of life
por: Garey, Kevin W, et al.
Publicado: (2023)

Gut microbiota and microbiota-based therapies for Clostridioides difficile infection
por: Chopra, Teena, et al.
Publicado: (2023)

Economic Impact of Recurrent Clostridioides difficile Infection in the USA: A Systematic Literature Review and Cost Synthesis
por: Reveles, Kelly R., et al.
Publicado: (2023)

Patient Perception of Route of Rectal Administration of Live Biotherapeutic Product for Recurrent Clostridioides difficile Infection
por: Feuerstadt, Paul, et al.
Publicado: (2023)

Microbiota restoration reduces antibiotic-resistant bacteria gut colonization in patients with recurrent Clostridioides difficile infection from the open-label PUNCH CD study
por: Langdon, Amy, et al.
Publicado: (2021)

Microbiota-Based Live Biotherapeutic RBX2660 for the Reduction of Recurrent Clostridioides difficile Infection in Older Adults With Underlying Comorbidities
por: Tillotson, Glenn, et al.
Publicado: (2022)

Role of the microbiome in essential metabolism in the human gut and its implications for Clostridioides difficile infection
por: Chopra, Teena, et al.
Publicado: (2023)

Safety of fecal microbiota, live-jslm (REBYOTA(™)) in individuals with recurrent Clostridioides difficile infection: data from five prospective clinical trials
por: Lee, Christine, et al.
Publicado: (2023)

Gut microbiota changes associated with Clostridioides difficile infection and its various treatment strategies
por: Gonzales-Luna, Anne J., et al.
Publicado: (2023)

236. Treatment of Recurrent Clostridioides difficile Infection With RBX2660 in Patients ≥ 65 Years Old With Underlying Comorbidities
por: Tillotson, Glenn S, et al.
Publicado: (2022)

1657 Who Seeks a Fecal Microbiota Transplant for Recurrent C. difficile Infection?: Patient Profile of the PUNCH CD Study
por: Orenstein, Robert, et al.
Publicado: (2014)

Transitions of care in Clostridioides difficile infection: a need of the hour
por: Khanna, Sahil, et al.
Publicado: (2022)

Evolution of clinical guidelines for antimicrobial management of Clostridioides difficile infection
por: Chaar, Abdelkader, et al.
Publicado: (2021)

Microbial ecology between Clostridioides difficile and gut microbiota
por: KAMIYA, Shigeru
Publicado: (2023)

1039. Rapid Restoration of Bile Acid Compositions After Treatment with RBX2660 for Recurrent Clostridioides difficile Infection—Results from the PUNCH CD3 Phase 3 Trial
por: Papazyan, Romeo, et al.
Publicado: (2021)

Heterogeneity of Randomized Controlled Trials of Fecal Microbiota Transplantation in Recurrent Clostridioides difficile Infection
por: Feuerstadt, Paul, et al.
Publicado: (2021)

Efficacy of Bezlotoxumab in Participants Receiving Metronidazole, Vancomycin, or Fidaxomicin for Treatment of Clostridioides (Clostridium) difficile Infection
por: Dubberke, Erik R, et al.
Publicado: (2020)

468 RBX2660 (microbiota suspension) for Recurrent C. difficile Infection: 60-Day Interim Analysis of the PUNCH-CD Phase 2 Safety Study
por: Dubberke, Erik, et al.
Publicado: (2014)

Gut microbiota features associated with Clostridioides difficile colonization in puppies
por: Berry, Alexander S. F., et al.
Publicado: (2019)

Insights into the Role of Human Gut Microbiota in Clostridioides difficile Infection
por: Kachrimanidou, Melina, et al.
Publicado: (2020)

Gut Microbiota Composition Associated with Clostridioides difficile Colonization and Infection
por: Martinez, Elisa, et al.
Publicado: (2022)

752. Costs Attributable to Clostridioides difficile Infection in the Presence of Differential Mortality
por: Sahrmann, John, et al.
Publicado: (2021)

Gut microbiota features associated with Clostridioides difficile colonization in dairy calves
por: Redding, Laurel E., et al.
Publicado: (2021)

Gut Microbiota Diversity of Preterm Neonates Is Associated With Clostridioides Difficile Colonization
por: Couturier, Jeanne, et al.
Publicado: (2022)

Healthcare Costs of Clostridioides difficile Infection in Commercially Insured Younger Adults
por: Sahrmann, John M, et al.
Publicado: (2023)

741. Antifungal Resistant Candida glabrata Are Most Commonly Colonized in Clostridioides difficile Infection (CDI) Patient Guts in Texas
por: Begum, Khurshida, et al.
Publicado: (2020)

Comparison of Risk Stratification Approaches to Identify Patients with Clostridioides difficile Infection at Risk for Multidrug-Resistant Organism Gut Microbiota Colonization
por: Zasowski, Evan J., et al.
Publicado: (2023)

Two-year durability of REBYOTA™ (RBL), a live biotherapeutic for the prevention of recurrent Clostridioides difficile infections
por: Orenstein, Robert, et al.
Publicado: (2023)

Emerging Options for the Prevention and Management of Clostridioides difficile Infection
por: Gonzales-Luna, Anne J., et al.
Publicado: (2023)

The Bacterial Gut Microbiota of Adult Patients Infected, Colonized or Noncolonized by Clostridioides difficile
por: Crobach, Monique J. T., et al.
Publicado: (2020)

Gut microbiota profiles in diarrheic patients with co-occurrence of Clostridioides difficile and Blastocystis
por: Vega, Laura, et al.
Publicado: (2021)

Gut Microbiota and Metabolite Changes in Patients With Ulcerative Colitis and Clostridioides difficile Infection
por: Wan, Jian, et al.
Publicado: (2022)

Increased Incidence and Risk of Septicemia and Urinary Tract Infection After Clostridioides difficile Infection
por: Olsen, Margaret A, et al.
Publicado: (2023)

471. Prevalence and Characteristics of Clostridioides difficile Infection in Bangladesh
por: Sofjan, Amelia K, et al.
Publicado: (2018)

2322: The effects of fecal microbiota transplantation on the gut microbiota in subjects with Clostridium difficile infection
por: Elizabeth Langdon, Amy, et al.
Publicado: (2018)

The burden of Clostridioides difficile infection in COVID-19 patients: A systematic review and meta-analysis
por: Granata, Guido, et al.
Publicado: (2022)

Gut metabolites predict Clostridioides difficile recurrence
por: Dawkins, Jennifer J., et al.
Publicado: (2022)

Integrating gut microbiome and host immune markers to understand the pathogenesis of Clostridioides difficile infection
por: Ke, Shanlin, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_vgqu6f0jgk36nni5d1ceebsd6q